About Tubulis
Tubulis develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company creates protein-drug conjugates with improved delivery, reduced toxicity, and enhanced therapeutic potential. Tubulis advances a pipeline of experimental drug candidates and collaborates with industry partners to expand oncology treatments. Its customers are partners and patients.
Company Details
Corporate & Operational Profile
Web & Domain Identity
Social & Network Presence
Company Milestones & Timeline
- Capital Raise
Raised $360,000,000 · Series-B+
startupintros.com
- Capital Raise
Raised $138,000,000 · Series-B+
- Capital Raise
Raised $63,000,000 · Series-B+
- Capital Raise
Raised $12,000,000 · Series-A
startupintros.com
- Milestone
Company founded
- Milestone
Website domain registered
tubulis.com
Investors & Backers
Funding History
Founders & Leadership
Björn Hock
Chief Development Officer
Christian Hackenberger
scientific co-founder
Dominik Schumacher
co-founder
Ingo Lehrke
CBO
Jonas Helma-Smets
CSO & Co-Founder
Press Coverage & Sources
startupintros.com/news/2025-10-01-tubulis-series-c
fundraisingfox.com/companies/tubulis-gmbh
endpts.com/german-adc-biotech-tubulis-raises-138m-to-enter-the-clinic-and-expand-in-us/
bioworld.com/articles/518452-adc-space-heats-up-as-tubulis-closes-63m-series-b-round
startupintros.com/news/2020-07-01-tubulis-series-a
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Hexagon Bio
hexagonbio.com
RefloDx
reflodx.com
HeyVoli
heyvoli.com
CureBay
curebay.com
4Tissue
4tissue.com